G2 and S phase-expressed protein 1 (GTSE1) (GTSE1)

G2 and S phase-expressed protein 1 (GTSE1) mRNA encodes a protein that is a critical regulator of the cell cycle and the p53 tumor suppressor pathway. The GTSE1 protein is primarily expressed during the S and G2 phases, where it binds to p53 and facilitates its nuclear export and subsequent degradation, thereby preventing p53-mediated apoptosis in response to DNA damage (Monte et al., 2003). Furthermore, GTSE1 is essential for mitotic spindle stability and accurate chromosome segregation by stabilizing microtubules (Bendre et al., 2016). Because GTSE1 is significantly overexpressed in multiple cancer types, including breast, lung, and hepatocellular carcinoma, and correlates with poor clinical outcomes and chemoresistance, its mRNA is a target for therapeutic intervention (Subramaniam et al., 2014). Inhibiting GTSE1 mRNA expression via RNA interference (RNAi) or antisense oligonucleotides (ASOs) aims to restore p53 function and induce mitotic defects, leading to selective apoptosis in rapidly dividing cancer cells (Lin et al., 2019). While no GTSE1-targeted therapies are currently FDA-approved, it remains a significant focus of preclinical oncology research due to its role in promoting genomic instability and cell survival.

Other names

B99GTSE-1G2 and S phase-expressed protein 1

Reduction of GTSE1 protein levels via mRNA degradation or translational inhibition to restore p53 activity and disrupt mitotic progression.